Institutional members access full text with Ovid®

Share this article on:

Partial cytogenetic response with toceranib and prednisone treatment in a young dog with chronic monocytic leukemia

Pérez, Mayrim L.a,*; Culver, Sarahc,*; Owen, Jennifer L.b; Dunbar, Markb; Kow, Kelvina; Breen, Matthewd,e; Milner, Rowan J.a

doi: 10.1097/CAD.0000000000000018
Case Report

Treatment of chronic monocytic leukemia (CMoL) in dogs has traditionally consisted of hydroxyurea. The use of tyrosine kinase inhibitors has been proposed as a treatment option for dogs with CMoL but has never been reported. We report a case of CMoL in a young dog that achieved clinical remission with treatment with the tyrosine kinase inhibitor toceranib and prednisone.

Departments of aSmall Animal Clinical Sciences

bPhysiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida

cDepartment of Molecular Biomedical Sciences

dDepartment of Molecular Biomedical Sciences and Center for Comparative Medicine and Translational Research, College of Veterinary Medicine, North Carolina State University, Raleigh

eCancer Genetics Program, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA

*Mayrim L. Pérez and Sarah Culver contributed equally to the writing of this article.

Correspondence to Rowan J. Milner, BVSc (Hons), MMedVet, PhD, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, 2015 SW 16th Avenue, PO Box 100126, Gainesville, FL 32610-0126, USA Tel: +1 352 294 4401; fax: +1 352 392 6125; e-mail:

Received April 17, 2013

Accepted July 31, 2013

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins